Ben Schlechter
@ben_schlechter
Husband’s husband. Doctor who runs towards the sick. Skier. Cook. Reader. Teacher. Democrat. Dog lover. @DanaFarber GI oncologist. @BIDMChealth alumnus.
ID: 1450648736389083140
20-10-2021 02:23:16
135 Tweet
337 Followers
404 Following
Keep up to date on the newest research and clinical application of immunotherapy treatments in colorectal cancer with leading experts Drs Ben Schlechter and Dr. Marwan G. Fakih. ms.spr.ly/6015g5WOF
🎥Ben Schlechter of Dana-Farber highlights the promising results of TAC01-HER2 in the TACTIC-2 trial for solid tumors. Efficacy seen in GEJ cancer warrants further investigation with checkpoint inhibitors: ➡️ow.ly/WhTV50OOq5S⬅️ #ASCO23 ASCO
Interesting podcast (transcript) on the #qualityoflife of older #colorectalcancer patients medscape.com/viewarticle/98… by Ben Schlechter and Nadine McCleary #crcsm
🎥Ben Schlechter of Dana-Farber highlights challenges in CAR T-cell therapies for solid tumors. Safe targets such as CLDN18.2 show promise, while established receptors like HER2 can cause severe toxicity: ➡️ow.ly/mt9E50ORVfF⬅️ #ImmunoOnc #CAR-T #ASCO23 ASCO
The artificial intelligence chatbot #ChatGPT has wowed some users with its seemingly human-like ability to generate and respond to language and worried others." Doug Rubinson & Ben Schlechter explore the potential benefits & challenges of ChatGPT in medicine: blog.dana-farber.org/insight/2023/0…
How do you know if your patient will benefit from liver-directed therapy for #colorectalcancer? Join experts Drs Ben Schlechter and AmmarSarwarIRad as they discuss. 🎧 #CCSM #OncTwitter ms.spr.ly/60129ZPmI
#her2 #gastriccancer Dana-Farber is now open and enrolling TACTIC-2, T-cell therapy for HER2+ gastric and esophageal cancers with at least one prior line of therapy. Great study to consider! clinicaltrials.gov/study/NCT04727…
Love science podcasts? If so, be sure to check out the Medscape #Colorectal Cancer Podcast segment, "Tumor Trash or Treasure #LiquidBiopsy for #Colorectal Cancer," by host Ben Schlechter with WCM Englander Institute for Precision Medicine's Dr. Pashtoon Kasi (Pashtoon Kasi MD, MS). medscape.com/viewarticle/10…
First effective use of immunotherapy for the most common subtype of #ColorectalCancer reported in Nature Medicine. This early-stage research shows promise for metastatic disease. #CancerResearch #ClinicalTrial CC: Dana-Farber Ben Schlechter Read more: ms.spr.ly/6016YAj9C
⭐ We spoke with Ben Schlechter of Dana-Farber on the unique mechanisms of action of botensilimab, and how this therapy is well-suited to treat microsatellite stable colorectal cancer, particularly in non-liver metastatic sites: buff.ly/4eKINoU